# Acumen Shares Fall More Than 80% After Alzheimer’s Trial Miss By John Kim Canonical URL: https://www.tokenpost.com/news/business/44782 Published: 2026-10-30T14:31:49.000Z Updated: 2026-10-30T14:31:49.000Z Section: Business > The midstage ALTITUDE-AD study tested sabirnetug. Acumen had $78.6 million in cash, cash equivalents and marketable securities as of Sept. 30. Acumen Pharmaceuticals (NASDAQ: ABOS) shares fell more than 80% in premarket trading Friday, Oct. 30, after the company announced its midstage Alzheimer’s trial missed primary and key secondary endpoints for its lead candidate, sabirnetug. The ALTITUDE-AD study tested sabirnetug in patients with Alzheimer’s disease. Acumen’s [third-quarter results]() put its cash, cash equivalents and marketable securities at $78.6 million as of Sept. 30. The company expected that balance to support clinical and operating activities into early 2027. ## Links in this article - [third-quarter results](https://www.tokenpost.com/news/business/40999)